ストックスクリーナーアプリを入手
70.94
1.76%
1.23
アフターアワーズ：
71.50
0.56
+0.79%
前日終値:
$69.71
開ける：
$68.352
24時間の取引高:
2.79M
Relative Volume:
1.05
時価総額：
$13.75B
収益：
$502.08M
当期純損益:
$-732.94M
株価収益率:
-18.75
EPS:
-3.7842
ネットキャッシュフロー:
$-455.50M
1週間 パフォーマンス:
-4.70%
1か月 パフォーマンス:
+1.78%
6か月 パフォーマンス:
+6.48%
1年 パフォーマンス:
+94.78%
1日の値動き範囲:
$68.35
$71.33
1週間の範囲:
$68.35
$84.75
52週間の値動き範囲:
$31.77
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
70.94 | 13.51B | 502.08M | -732.94M | -455.50M | -3.7842 |
VRTX
Vertex Pharmaceuticals Inc
|
423.24 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
776.02 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.19 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.80 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-09 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-03-10 | 開始されました | William Blair | Outperform |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2026-01-06 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-11 | 開始されました | Bernstein | Outperform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-14 | 開始されました | Jefferies | Buy |
| 2025-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore (NASDAQ:BBIO) - Seeking Alpha
BridgeBio rises after late-stage trial win for dwarfism therapy - MSN
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $96 to $157 - Moomoo
BridgeBio earnings on deck: Can Attruby sustain rapid growth? By Investing.com - Investing.com India
BridgeBio earnings on deck: Can Attruby sustain rapid growth? - Investing.com
BBIO Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus
BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
H.C. Wainwright reiterates BridgeBio Pharma stock rating on stable Vyndamax outlook - Investing.com Canada
BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - MSN
BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman By Investing.com - Investing.com South Africa
BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman - Investing.com UK
BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity - Investing.com Canada
Raymond James reiterates BridgeBio stock rating on Vyndamax settlement By Investing.com - Investing.com Canada
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $106 - Moomoo
BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) - MSN
BBIO Reiterated by Mizuho -- Price Target Maintained at $106 - GuruFocus
Barclays sees Pfizer IP case progress as positive for BridgeBio stock - Investing.com Canada
BridgeBio (BBIO) Q2 2025 Earnings Transcript - The Globe and Mail
Barclays reiterates Overweight on BridgeBio Pharma stock at $157 By Investing.com - Investing.com Canada
Mizuho reiterates BridgeBio Pharma stock rating on Vyndamax patent news By Investing.com - Investing.com South Africa
RBC Capital reiterates BridgeBio Pharma stock rating on patent clarity By Investing.com - Investing.com Canada
William Blair reiterates BridgeBio stock rating after Pfizer settlement By Investing.com - Investing.com Canada
Mizuho reiterates BridgeBio Pharma stock rating on Vyndamax patent news - Investing.com
BridgeBio (BBIO) Shares Surge Following Pfizer Patent Settlement - GuruFocus
Mizuho reiterates BridgeBio stock rating on patent settlement news By Investing.com - Investing.com Canada
BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) (BBIO:NASDAQ) - Seeking Alpha
BBIO Stock Draws Bulls As Rare-Disease Pipeline Gains Steam - StocksToTrade
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
(BPRW) BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White - Black PR Wire
Morgan Freeman joins push on a heart disease often mistaken for heart failure - Stock Titan
Wells Fargo Maintains BridgeBio Pharma (BBIO) Overweight Recommendation - MSN
BridgeBio says new Attruby data adds to benefit in ATTR-CM - MSN
H.C. Wainwright reiterates BridgeBio stock rating on patent case developments - Investing.com Canada
BridgeBio Pharma gains as investors refocus on pipeline catalysts ahead of expected earnings - Quiver Quantitative
Piper Sandler reiterates BridgeBio stock rating on patent settlement By Investing.com - Investing.com Canada
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100 - Moomoo
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: A Deep Dive Into Its 37.18% Potential Upside - DirectorsTalk Interviews
BBIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Barclays initiates coverage of BridgeBio Pharma (BBIO) with overweight recommendation - MSN
MSN Money - MSN
BridgeBio Pharma prices $550M convertible bond offering - MSN
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is It Too Late To Consider BridgeBio Pharma (BBIO) After Its 101.8% One-Year Surge? - Yahoo Finance
There Are Early Signals Ahead of Tafamidis Trial As Analysts See Potential Upside for Pfizer (PFE) and BridgeBio Pharma (BIO) - Markets Herald
[ARS] BridgeBio Pharma, Inc. SEC Filing - Stock Titan
BridgeBio (NASDAQ: BBIO) schedules 2026 virtual meeting, pay and equity plan votes - Stock Titan
BridgeBio (BBIO) Shares Rise Following Positive Patent Settlemen - GuruFocus
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.39%
0.10%
大文字化:
|
ボリューム (24 時間):